<DOC>
	<DOCNO>NCT02914990</DOCNO>
	<brief_summary>The main objective study evaluate safety tolerability BPI-15086 .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Profile BPI-15086 EGFR T790M Mutation-positive NSCLC Patients</brief_title>
	<detailed_description>The main objective study evaluate safety tolerability BPI-15086 . In addition , anti-cancer effect BPI-15086 EGFR T790M mutation-positive advance NSCLC patient progress previous EGFR tyrosine kinase inhibitor therapy also evaluate . Biomarkers related efficacy BPI-15086 investigate .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm , locally advanced metastatic NSCLC patient , suitable surgery radiotherapy Radiological documentation disease progression previous continuous EGFR TKI ( e.g . icotinib , gefitinib , afatinib , neratinib , dacomitnib , erlotinib ) treatment Patients must fulfil one following : Confirmation tumour harbour EGFR sensitivity mutation ( exon 19 deletion , L858R L861R , G719X ) Must experience clinical benefit EGFR TKIs , accord Jackman criterion Confirmation T790M mutation positive disease progression EGFR TKIs Eastern Cooperative Oncology Group ( ECOG ) performance status 02 estimate life expectancy least 12 week Measurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST1.1 ) Adequate bone marrow , hepatic , renal function Have sign Informed Consent Form Any malignancy within 5 year first dose study treatment Radiotherapy target lesion within 4 week first dose study treatment . Investigational agent anticancer drug ( Including cytotoxic chemotherapy ) previous treatment regimen clinical study within 14 day first dose study treatment Prior treatment third generation EGFR TKIs , include osimertinib , rociletinib , EGF816 , olmutinib , ASP8273 avitinib Brain/meninges metastases unless asymptomatic , stable require steroid least 4 week prior start study treatment History interstitial lung disease , druginduced interstitial lung disease , radiation pneumonitis require steroid treatment , evidence clinically active interstitial lung disease , radiological documentation idiopathic pulmonary fibrosis baseline ; uncontrolled pleural effusion/pericardial effusion Any evidence severe uncontrolled systemic disease , include CTCAE 2 high active infection , uncontrolled hypertension , unstable angina pectoris , congestive cardiac failure severe liver/renal metabolic disease Active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) History organ transplant ; surgery severe injury within 4 week Any clinically important abnormality rhythm , conduction morphology rest ECG eg , complete leave bundle branch block , third degree heart block , second degree heart block , PR interval &gt; 240msec , QRS &gt; 110 msec Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age first degree relative concomitant medication know prolong QT interval Poorly control hyperglycemia ( fast blood glucose level â‰¥7.0 mmol/L ) . Any unresolved toxicity prior therapy great Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 time start study treatment exception alopecia Refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate product previous significant bowel resection would preclude adequate absorption BPI15086</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>